Evidence map›Paper›PMID 34461843›Full record

ReviewBMC nephrology2021

Acute tubulointerstitial nephritis associated with antineutrophil cytoplasmic antibody following cimetidine treatment: a case report.

Keita Morimoto, Go Kanzaki, Takahito Niikura, Kentaro Koike, Nanae Matsuo, Yukio Maruyama, Nobuo Tsuboi, Takashi Yokoo

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in BMC nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Keita MorimotoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, 105-8461, Tokyo, Japan.
Go KanzakiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, 105-8461, Tokyo, Japan. g-kanzaki@jikei.ac.jp.ORCID 0000-0002-7795-369X
Takahito NiikuraDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, 105-8461, Tokyo, Japan.
Kentaro KoikeDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, 105-8461, Tokyo, Japan.
Nanae MatsuoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, 105-8461, Tokyo, Japan.
Yukio MaruyamaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, 105-8461, Tokyo, Japan.
Nobuo TsuboiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, 105-8461, Tokyo, Japan.
Takashi YokooDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, 105-8461, Tokyo, Japan.
Jikei University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntineutrophil cytoplasmic antibody (ANCA)-associated vasculitis usually induces rapidly progressive glomerulonephritis, including pauci-immune necrotizing crescentic glomerulonephritis. Acute tubulointerstitial nephritis (ATIN), which is often drug-induced, is a frequent cause of kidney injury. However, ATIN associated with ANCA without any glomerular lesions has been rarely reported, and drug-induced ATIN associated with ANCA is not well recognized. Here we present a case of an older woman with ATIN associated with myeloperoxidase-ANCA (MPO-ANCA) following cimetidine treatment. CASE PRESENTATION: A 70-year-old woman was admitted to our hospital due to acute kidney injury and mild proteinuria. She had a one-year history of chronic thyroiditis and dyslipidemia, for which she was taking levothyroxine sodium and atorvastatin, respectively. Two weeks before admission she had started cimetidine, methylmethionine sulfonium chloride, and itopride hydrochloride for gastric discomfort persistent since a month. She had experienced fatigue for two weeks and later appetite loss. The patient demonstrated a positive titer for MPO-ANCA (192 IU/mL) and a positive drug-induced lymphocyte stimulation test for cimetidine. She underwent two kidney biopsies that revealed ATIN without any glomerular lesions. Despite discontinuation of cimetidine on admission, renal injury continued with the presence of high MPO-ANCA titer. Oral steroid treatment was closely related with the recovery of her renal function and disappearance of MPO-ANCA.

conclusionsIn this case, ATIN presented as sustained renal insufficiency and high MPO-ANCA titer despite withdrawal of cimetidine. Therefore, we reason that the development of ANCA-associated ATIN was caused by cimetidine. Serologic follow-up with measurement of MPO-ANCA titers and renal biopsy are recommended when the clinical history is inconsistent with the relatively benign course of drug-induced ATIN.

Indexed as

AdultAgedAntibodies, Antineutrophil CytoplasmicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisCimetidineCytochrome P-450 CYP1A2 InhibitorsFemaleHumansKidneyMaleMiddle AgedNephritis, InterstitialAntibodies, Antineutrophil CytoplasmicCimetidineCytochrome P-450 CYP1A2 InhibitorsAcute tubulointerstitial nephritisAntineutrophil cytoplasmic antibody-associated vasculitisCimetidinMyeloperoxidase-antineutrophil cytoplasmic antibody

Identifiers

PMID34461843
PMCPMC8404249
OpenAlexW3196341033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.